Search the Blog
Submit
Displaying 11 - 20 of 598 blog posts

New study: Colorectal cancer cases climbing in young people

I mentioned last week that a number of exciting developments are taking place for colorectal cancer research and care. Our hope is that through these projects, we’ll be able to better understand this disease, with the end goal of improving outcomes for the roughly 4,000 diagnosed every year in British Columbia. Today, I’ll tell you a bit more about these developments. new trial provides deeper insight on treatment plans We recently completed a cross-Canada clinical trial testing immunotherapy for colorectal cancer. Previously, it has been shown that immunotherapy works for the five per cent...

New research underway to improve colorectal cancer outcomes

Hello, My name is Dr. Jonathan Loree. I’m a medical oncologist at BC Cancer, specializing in gastrointestinal cancer treatment and research. It is my first time blogging for the BC Cancer Foundation. This month is Colorectal Cancer Awareness Month, and I’m excited to share with our community the latest advancements in this field. Colorectal cancer remains one of the most common and lethal cancer types in our province, affecting close to 4,000 British Columbians every year. Promising new research now underway is helping us understand the disease and how it develops in different patients. This...

Introducing March guest blogger Dr. Jonathan Loree

Thank you to Dr. Stephen Lam for sharing the results of his game-changing study on lung cancer incidence and screening. It is pleasing to hear of the significant strides BC Cancer has made in this area, and how our donors continue to help bring forth new prevention and treatment strategies. I am pleased to welcome Dr. Jonathan Loree, medical oncologist, to our blog for the month of March – Colorectal Cancer Awareness Month. Dr. Loree is a new recruit to BC Cancer, where he specializes in colorectal cancer research and care. He will share a number of exciting initiatives underway to improve...

How researchers can detect cancer risk in breath

While lung cancer continues to be among the deadliest diseases today, we know this will change as we find new and more effective ways to detect it earlier. Indeed, we estimate that approximately 80 per cent of those with lung cancer may survive if caught at an earlier stage. As we look toward the future, there are many projects in the works that will help achieve this aim. Using the breath to detect cancer risk With generous support from the BC Cancer Foundation and its donors, we hope to establish what we call a Breathomics laboratory that will detect cancer risk in the breath. The body...

Pollution accounts for 23% of lung cancer deaths, research finds

By next year, we project that lung cancer will be the fifth highest killer among all cancer and non-cancer diseases across Canada. Only about 18 per cent of patients survive five years or more, simply because symptoms often don’t show until it’s too late. With our research, we know that lung cancer is treated earlier – before it spreads outside the air passages – we can change this. We project that over 80 per cent of those with early lung cancer - what we call Stage IA - can survive if the disease is caught early and treatment started. Cynthia’s story: highlighting the importance of early...

Asian women more at risk for lung cancer, research finds

Hello, My name is Dr. Stephen Lam. I'm a distinguished scientist at BC Cancer and the Leon Judah Blackmore Foundation chair in lung cancer research. I'm also the MDS - Rix endowed director of translation lung cancer research and chair of the Provincial Lung Tumour Group at BC Cancer. It has been three years since I last blogged for the BC Cancer Foundation. I am thrilled to report back on the progress we've made to advance research for this disease since. Lung cancer remains deadly, but progress on horizon Lung cancer remains among the deadliest and most prevalent cancers in B.C., Canada and...

Introducing February guest blogger Dr. Stephen Lam

Thank you to Dr. Poul Sorensen for sharing his translational efforts in pediatric cancer research with our community. It is always inspiring to hear how donor-funded research continues to make a tangible difference in the lives of those affected by cancer. I am pleased to welcome Dr. Stephen Lam, distinguished scientist and Leon Judah Blackmore Chair in lung cancer research, back to our blog for February. Dr. Lam’s most recent efforts have uncovered women of Asian descent to be up to several times more susceptible to lung cancer than men in cities with poor air quality. He will explain these...

How donors catalyze cancer research & care

I can’t overstate the importance of philanthropy in our efforts to research new and more effective treatments for cancer. It would be easy enough for granting agencies to deny funding based on a disease being rare. But it’s clear, based on our most recent findings, that this is the wrong approach. If you spearhead science for the sake of discovery, then you really can uncover things that have a broad application that you wouldn’t have been able to find had you followed purely where the money is. This is where Foundation donors play such a key part, as they are really instrumental in our quest...

STRESS SIGNALLING IN TUMOUR CELLS

Last week I told you about a breakthrough discovery that lead to the development of a new drug that targets 22 different types of cancers. This week I am eager to share about another exciting development our team has been focusing on: stress signalling in tumour cells. In particular, how tumour cells adapt to stress. The idea is that when tumour cells grow in a certain environment, that environment then has the capability to ‘stress’ the tumour cells – for example, there might not be enough oxygen, there might be an immune cell attack or DNA damaging agents that then activate the stress...

TWO DECADES OF DISCOVERY IMPACTS 22 TYPES OF CANCERS

Hello, My name is Dr. Poul Sorensen and I am a distinguished scientist at BC Cancer. I am thrilled to have the opportunity to be blogging once again and share some exciting developments in childhood cancer research. One of our most significant breakthroughs involved a gene mutation in a rare pediatric cancer that was originally discovered in our lab back in 1998. Twenty years of progress later, that original discovery has now led to a new drug called Larotrectinib – just recently FDA approved in 2018– that targets at least 22 different types of cancers. To see two decades worth of research...

Pages